Articles from Korsana Biosciences, Inc.

Korsana Biosciences, Inc. (“Korsana” or the “Company”), a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced the appointments of Matthew Leoni, M.D., as Chief Medical Officer, Gan Wei, Ph.D., as Chief Technical Officer, and Heidi Henson as a member of its Board of Directors, where she will serve as Chair of the Audit Committee. Collectively, these appointments strengthen Korsana's leadership team as the Company advances KRSA-028, its lead THETA™-enabled therapeutic candidate for Alzheimer's disease, toward clinical development while continuing to progress its pipeline of potential best-in-class therapies for neurodegenerative diseases.

Korsana Biosciences, Inc. (“Korsana” or the “Company”), a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced that Mark Vignola, Ph.D., has joined as Chief Financial Officer (CFO). Dr. Vignola brings extensive leadership experience in corporate finance across the biotech industry.

Korsana Biosciences, Inc. (“Korsana” or the “Company”), a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer, will present at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 3:00 pm ET.

Korsana Biosciences, Inc. (“Korsana” or the “Company”), a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced its emergence from stealth, with backing from a leading syndicate of healthcare investors. The Company was founded in 2024 with a $25 million seed investment from Fairmount and Venrock Healthcare Capital Partners. In September 2025, the Company closed a $150 million private Series A financing co-led by Wellington Management and TCGX, with participation by J.P. Morgan Life Sciences Private Capital, Janus Henderson Investors, Sanofi Ventures, Foresite Capital, and others. This funding is being used to develop potential best-in-class therapeutics to treat neurodegenerative diseases, with an initial focus on Alzheimer’s disease.